An interventional study of Sat75 and Sat50 in Premature Infants, Bronchopulmonary Dysplasia and Intraventricular Hemorrhage, sponsored by University of Texas Southwestern Medical Center. Recruiting at 1 site in United States. Open to participants aged 0 Minutes to 10 Minutes. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University of Texas Southwestern Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 742 studies in Premature Birth with a site in United States — 103 open to participants now, 136 under way, 9 of them phase 3. Premature Birth · United States.
Among the 742 studies in Premature Birth with a site in United States, this one is the 53rd largest by planned enrollment of the 529 interventional ones that give a count, is one of 19 that started in 2024, is one of 357 with no phase, reaches primary completion later than 96 of the 135 other live ones, and was the 661st registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →103 of the 742 studies in Premature Birth with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 0 days–9 mo
University of South Carolina · Sites in United States
Ages 18+ · Women only
Columbia University · Sites in United States
Ages 18–40 · Women only
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18+ · Women only · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 1 days–3 days
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 0 Minutes to 10 Minutes · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
742 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 68 · Phase 3 66 · Phase 4 23
First in 1987; this study’s year is marked. 19 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 700 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 85 across the 529 interventional studies, 104 across the 209 observational. Of the 542 that completed or were terminated, 145 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 742 have an industry lead sponsor. The 10 most frequent:
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 200 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
University of Texas Southwestern Medical Center has 8 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
46 of the studies in Premature Birth with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04614714Phase 3University of California, DavisMilk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants | 2027-08-30 |
| NCT03797183University of Colorado, DenverGenesis Electrical Impedance Tomography (EIT): A Preliminary Study | 2026-11 |
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT01483079Baylor College of MedicinePost-Discharge Growth of Infants Who Received Donor Human Milk Products in the Neonatal Intensive Care Unit (NICU) | 2026-12 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
Add all 46 to your calendar (.ics) → With an account.
Among the 742 studies in Premature Birth with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to answer one of the fundamental gaps in knowledge in the resuscitation of preterm infants at birth: What is the optimal target oxygen saturation (SpO2) range that increases survival without long-term morbidities? Oxygen (O2) is routinely used for the stabilization of preterm infants in the delivery room (DR), but its use is linked with mortality and several morbidities including bronchopulmonary dysplasia (BPD). To balance the need to give sufficient O2 to correct hypoxia and avoid excess O2, the neonatal resuscitation program (NRP) recommends initiating preterm resuscitation with low (≤ 30%) inspired O2 concentration (FiO2) and subsequent titration to achieve a specified target SpO2 range. These SpO2 targets are based on approximated 50th percentile SpO2 (Sat50) observed in healthy term infants. However, the optimal SpO2 targets remain undefined in the preterm infants. Recent data suggest that the current SpO2 targets (Sat50) may be too low. The investigators plan to conduct a multicenter RCT of Sat75 versus Sat50 powered for survival without BPD. The investigators will randomize 700 infants, 23 0/7- 30 6/7 weeks' GA, to 75th percentile SpO2 goals (Sat75, Intervention) or 50th percentile SpO2 goals (Sat50, control). Except for the SpO2 targets, all resuscitations will follow NRP guidelines including an initial FiO2 of 0.3. In Aim 1, the investigators will determine whether targeting Sat75 compared to Sat50 increases survival without lung disease (BPD). In addition, the investigators will compare the rates of other major morbidities such as IVH. In Aim 2, the investigators will determine whether targeting Sat75 compared to Sat50 increases survival without neurodevelopmental impairment at 2 years of age. In Aim 3, the investigators will determine whether targeting Sat75 compared to Sat50 decreases oxidative stress.
Purpose: Oxygen is the most commonly used drug during preterm resuscitation, but its use has been linked to mortality and several morbidities such as bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), and retinopathy of prematurity (ROP).Preterm infants at birth are more vulnerable to oxygen toxicity caused by exposure to high concentrations of oxygen during resuscitation, but are also equally vulnerable to the adverse effects of suboptimal oxygen use in the delivery room. To balance the need to give sufficient O2 to correct hypoxia and to avoid excess O2, the NRP recommends initiating preterm resuscitation with low FiO2 (≤ 0.3) and subsequent titration to achieve specified target O2 saturations (SpO2). These SpO2 targets (Sat50) are based on approximated 50th percentile SpO2 values of minute per minute pre-ductal SpO2 observed in healthy term newborns who were born vaginally at sea level, breathing spontaneously and did not need any oxygen at birth. Current SpO2 targets are based on expert opinion. In the absence of studies comparing different SpO2 targets, Sat50 was selected by experts at the International Liaison Committee On Resuscitation (ILCOR) and NRP to balance the need for O2 supplementation and avoid excess O2 exposure. Ranges were adjusted by NRP so that they could be memorized easily. However, a recently published study suggested that the currently recommended Sat50 targets are lower than 50th percentile SpO2 values for term infants who undergo delayed cord clamping. Recent studies suggest that the currently recommended Sat50 SpO2 targets may be too low to promote an adequate drop in pulmonary vascular resistance in preterm infants and may be harmful. Recent studies raise concern that the Sat50 strategy may be associated with poorer breathing efforts, higher IVH and higher mortality. The majority of research in O2 use during preterm resuscitation has focused on the starting FiO2, while SpO2 targets have received very little attention. The investigators propose a paradigm shift by changing the research focus to determine the optimal target SpO2 range instead of the initial FiO2. The investigators propose a novel O2 strategy where resuscitation is initiated with 0.3 FiO2 and is titrated every 30 seconds to meet target SpO2 roughly based on the 75th percentile of Dawson curves (Sat75) compared to the 50th percentile of Dawson curves (Sat50). Preliminary data from principal investigator's NICHD K23 funded pilot RCT of 75 preterm infants \<31 weeks' gestational age (GA) demonstrated that infants randomized to 75th percentile SpO2 goals (Sat75) had a lower incidence of SpO2 \<80% at five minutes and lower duration of bradycardia and PPV in the DR compared to infants randomized to 50th percentile SpO2 goals (Sat50). Although not powered for this analysis, Sat75 infants had less pulmonary hypertension and higher survival without BPD. The investigators hypothesize that the Sat75 strategy results in better pulmonary transition, less time with low SpO2 and lower oxidative stress resulting in a lower incidence of neonatal morbidities such as BPD, IVH, ROP and higher survival without BPD.
Hypothesis: The primary hypothesis is that delivery room resuscitation of preterm infants \< 31 weeks' GA with Sat75 targets compared to Sat50 targets will result in increased survival without BPD at 36 weeks' postmenstrual age (PMA).
Study design: A prospective multicenter randomized controlled trial of Sat75 versus Sat50 will be conducted. As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2 in both intervention and control groups. The study intervention is the Sat75 where FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. The control group is the Sat50 where FiO2 will be titrated by 0.2-0.3 every 30 seconds to achieve the NRP recommended target SpO2 which approximates the 50th percentile SpO2 observed in healthy term newborns. In the rare event, where chest compressions are needed during delivery room resuscitation, the FiO2 will be increased to 1.0 as per current NRP guidelines. Once the heart rate (HR) is stabilized, the FiO2 will be reduced to meet the target SpO2. Apart from the randomly assigned target SpO2, resuscitation will follow current NRP guidelines. Assignment to the Sat75 or Sat50 group will use a 1:1 allocation ratio and stratification by GA: 23 0/7 to 27 6/7 weeks and 28 0/7 to 30 6/7 weeks. Demographics, perinatal variables, resuscitation characteristics and neonatal morbidity-mortality data and data of Neurodevelopmental follow-up at around 2 years of age will be electronically recorded using the web-based data entry system developed by the Data Coordinating Center.
Analysis plan: An intention to treat analysis of all randomized infants who received study intervention and have a post-randomization study measurement will be conducted. Baseline characteristics of the newborns will be compared between treatment groups. Descriptive statistics such as mean, SD, median, and range will be used to summarize continuous variables in each study group; frequencies and percentages will be presented for categorical variables. The groups will be formally compared using Student's t-tests and Wilcoxon rank-sum tests, as appropriate, for continuous variables. The chi-square test of association and Fisher's exact test will be used for categorical variables as appropriate.
The primary analysis will be based on the chi-square test of association. Rates of survival without BPD will be presented with 95% confidence intervals. Multivariable logistic regression models (for odds ratios), or modified Poisson regression models with robust standard errors (for risk ratios), will be used to adjust for any imbalanced baseline characteristics. Any characteristics identified as being imbalanced at baseline will be considered as covariates. The primary analysis plan assumes that the intra-class correlation among infants of multiple gestations will be negligible. As sensitivity analyses, generalized estimating equations with robust standard errors will be used to account for clustering effects within siblings. Statistical analysis will be performed with SAS software version 9.4 (SAS Institute, Cary NC). A two-sided 0.05 level of significance will be used and no interim analysis is planned. Data collection protocols will be implemented to minimize missing data. The investigators will conduct 'Per Protocol' analysis and 'As Treated' analysis strictly as secondary analyses to evaluate the impact of time spent outside the group target SpO2 on clinical outcomes. Further, the investigators will conduct pre-planned analyses to examine possible site by testing site by treatment interactions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Neonates with OB gestational age 22-30 weeks
Exclusion Criteria:
FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth.
Other: Sat75
FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve NRP recommended target SpO2 which approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth.
Other: Sat50
As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
Survival without BPD
The primary outcome for this trial is survival without BPD at 36 weeks' PMA. Both components, death and BPD, will also be reported separately. Neonatal mortality during the NICU stay, the postnatal day at the time of mortality and the primary cause of mortality will be recorded. BPD will be defined as the need for any form of positive airway pressure support or supplemental O2 at 36 weeks' PMA.BPD will be graded as mild, moderate and severe as per the NICHD consensus definition. All eligible infants will undergo room air challenge at 36 weeks' PMA for the physiologic definition of BPD.
Time frame: 36 weeks Postmenstrual Age
Bronchopulmonary Dysplasia
BPD will be defined as the need for any form of positive airway pressure support or supplemental O2 at 36 weeks' PMA.BPD will be graded as mild, moderate and severe as per the NICHD consensus definition. All eligible infants will undergo room air challenge at 36 weeks' PMA for the physiologic definition of BPD. In addition, BPD by Jensen Criteria will also be used as a secondary outcome. Respiratory support at 40 weeks PMA and at discharge will also be collected
Time frame: 36 weeks PMA, 40 weeks PMA and at Discharge
Oxygen saturations in the delivery room
High resolution SpO2 data with 2 second frequency from pulse oximeter will be collected. Average Spo2 value every 30 seconds will be plotted. The investigators will also calculate time spent in the desired target, above the target or below the target.
Time frame: First 15 minutes after birth
SpO2<80% at 5 minutes after birth
SpO2\<80% at 5 minutes after birth
Time frame: First 5 minutes after birth
Delivery Room Intubation
The investigators will record if the newborn was intubated in the delivery room
Time frame: Up to first 30 minutes after birth
Receipt of chest compressions and epinephrine
In the rare event of the need for full CPR, data will be abstracted from the DR code documentation. FiO2 will be adjusted to 1.0 until return of spontaneous circulation and then titrated to achieve the randomized target SpO2.
Time frame: Up to first 30 minutes after birth
Severe Intraventricular hemorrhage
Severe Intraventricular hemorrhage
Time frame: From date of randomization until the date of first documented diagnosis or date of death from any cause or date of discharge, whichever came first, assessed up to 12 months
Severe Retinopathy of Prematurity
Severe Retinopathy of Prematurity
Time frame: From date of randomization until the date of first documented diagnosis or date of death from any cause or date of discharge, whichever came first, assessed up to 12 months
Length of hospitalization
Length of hospitalization
Time frame: From date of randomization until the date of first documented diagnosis or date of death from any cause or date of discharge, whichever came first, assessed up to 12 months
Necrotizing Enterocolitis (NEC)
Necrotizing enterocolitis will be defined ≥ Stage 2 based on the modified Bell criteria.
Time frame: From date of randomization until the date of first documented diagnosis or date of death from any cause or date of discharge, whichever came first, assessed up to 12 months
Neurodevelopmental Impairment (NDI)
Moderate to severe neurodevelopmental impairment will be defined as Bayley III Cognitive \<85, Bayley III Motor \<85, gross motor functional classification system (GMFCS) 2 or greater, or bilateral "blind" despite corrective lenses or bilateral no functional hearing with or without amplification
Time frame: From date of randomization until the date of first documented diagnosis or date of death from any cause or date of discharge, whichever came first, assessed up to 36 months
Oxidative Stress
8-Isoprostanes and 8-OHdG will be measured in serum and urine samples
Time frame: from time of randomization to the first 24 hours after birth
Plan to share: Yes — Data will be made available per NICHD requirements (National Institute of Child Health and Human Development). Researchers can email the PI for more information at vishal.kapadia@utsouthwestern.edu
Supporting information: Clinical study report
Time frame: After the completion of data analysis and manuscript publication.
Access criteria: An archived dataset with documentation will be made available for additional uses by outside investigators, in collaboration with the study investigators.
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Apr 2028, 49 months after the start.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 49 months is above that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center →